Cargando…

A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate

OBJECTIVE: Interleukin (IL)-12 and IL-23 have been implicated in the pathogenesis of rheumatoid arthritis (RA). The safety and efficacy of ustekinumab, a human monoclonal anti-IL-12/23 p40 antibody, and guselkumab, a human monoclonal anti-IL-23 antibody, were evaluated in adults with active RA despi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smolen, Josef S, Agarwal, Sandeep K, Ilivanova, Elena, Xu, Xie Lillian, Miao, Ye, Zhuang, Yanli, Nnane, Ivo, Radziszewski, Waldemar, Greenspan, Andrew, Beutler, Anna, Baker, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530337/ https://www.ncbi.nlm.nih.gov/pubmed/28087506 http://dx.doi.org/10.1136/annrheumdis-2016-209831

Ejemplares similares

The use of ustekinumab and guselkumab in a pediatric psoriasis patient with active hepatitis B infection
por: Song, Eingun James, et al.
Publicado: (2020)

Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab
por: Campbell, Kim, et al.
Publicado: (2023)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate‐to‐severe plaque psoriasis: the COMPASS analysis
por: Diels, J., et al.
Publicado: (2020)

The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate
por: Mojtahed Poor, Sorwe, et al.
Publicado: (2023)

Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
por: Smolen, Josef S, et al.
Publicado: (2014)

Ustekinumab pharmacokinetics after subcutaneous administration in swine model
por: Grabowski, Tomasz, et al.
Publicado: (2021)

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
por: Hampton, Philip, et al.
Publicado: (2021)

Evaluating Potential Disease‐Mediated Protein‐Drug Interactions in Patients With Moderate‐to‐Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab
por: Zhu, Yaowei, et al.
Publicado: (2020)

Guselkumab for plaque psoriasis
Publicado: (2019)

Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center
por: Jung, Seung-Won, et al.
Publicado: (2022)

Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing
por: Argüelles-Arias, Federico, et al.
Publicado: (2023)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Subcutaneous Sweet Syndrome Successfully Treated With Ustekinumab in a Patient With Ulcerative Colitis
por: Hu, Kelly A., et al.
Publicado: (2022)

The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients – preliminary report
por: Owczarczyk-Saczonek, Agnieszka, et al.
Publicado: (2018)

Guselkumab for the treatment of psoriasis – evidence to date
por: Nogueira, Miguel, et al.
Publicado: (2019)

Guselkumab: widened action in psoriatic disease
por: Arnone, Marcelo, et al.
Publicado: (2021)

Tolerability and Patient/Physician Satisfaction with Subcutaneously Administered Methotrexate Provided in Two Formulations of Different Drug Concentrations in Patients with Rheumatoid Arthritis
por: Müller-Ladner, Ulf, et al.
Publicado: (2010)

Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience
por: Demary, Winfried, et al.
Publicado: (2014)

Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis
por: Chen, Yang, et al.
Publicado: (2021)

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate
por: Smolen, Josef S, et al.
Publicado: (2018)

Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease
por: Kakiuchi, Toshihiko, et al.
Publicado: (2021)

Eczematous eruption after guselkumab treatment for psoriasis
por: Reyn, Birgit, et al.
Publicado: (2019)

Modified dose of guselkumab for treatment of pyoderma gangrenosum
por: Reese, Ashley M., et al.
Publicado: (2022)

Arthritis Interception in Patients with Psoriasis Treated with Guselkumab
por: Zabotti, Alen, et al.
Publicado: (2021)

Successful Treatment of Recalcitrant Palmoplantar Pustulosis with Guselkumab
por: Jung, Jang Hwan, et al.
Publicado: (2023)

Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis
por: Vena, Gino Antonio, et al.
Publicado: (2018)

Influence of ustekinumab on body weight of patients with psoriasis: an initial report
por: Owczarczyk-Saczonek, Agnieszka, et al.
Publicado: (2014)

Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study
por: Gossec, Laure, et al.
Publicado: (2023)

Bioavailability of IgG Administered by the Subcutaneous Route
por: Berger, Melvin, et al.
Publicado: (2013)

The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab
por: Chiu, Hsien-Yi, et al.
Publicado: (2015)

Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab
por: Kashlan, Reem, et al.
Publicado: (2021)

Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective
por: Yamamoto, Toshiyuki
Publicado: (2021)

Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum
por: Baier, Cassandra, et al.
Publicado: (2020)

Successful treatment with cyclosporine and guselkumab for pityriasis rubra pilaris
por: Nishimura, Mai, et al.
Publicado: (2022)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
por: Martora, Fabrizio, et al.
Publicado: (2023)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
por: Bartholomew, Erin, et al.
Publicado: (2023)

Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Guselkumab for the treatment of severe refractory psoriasis in a pediatric patient
por: Kim, Sa Rang, et al.
Publicado: (2019)

Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Nakamura, Mio, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3q83cm1bhehcv35d15vi4rfjqr